Fairvalue-Calculator Fairvalue-Calculator
EN DE

Exosens, (EXENS) Fair Value & Analysis

Industrials · FR · Market cap €3.5B

Price€57.95
Fair Value€17.61
Upside-69.6%
Quality95/100
Evidence: High Range €11.48 – €22.01

Analysis

Exosens, (EXENS) currently trades at €57.95, while our model-based Fair Value estimate is €17.61 — implying the stock looks roughly 69.6% overvalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging. The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and components, such as phosphor screens, resistive glass products, microchannel plates, and electron generator arrays. It also provides bare and energy compensated Geiger- Müller tubes; gamma and neutron detectors; mineral insulated extensions; and silicon photodiodes, as well as methane airborne detection solutions. The company sells its products under the Exosens, Photonis, Xenics, Telops, El-Mul, and Noxant brand names. It serves defense and su…

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.